Tiny capsules deliver brain cancer drugs by ‘electrojet’
Drugs delivered in consistently uniform microcapsules may offer an easier, more tightly controlled way to treat brain cancer.
“Brain tumors are one of the world’s deadliest diseases,” says Mohammad Reza Abidian, assistant professor of bioengineering, chemical engineering, and materials science at Penn State. “Typically doctors resect the tumors, do radiation therapy, and then chemotherapy.”
The majority of chemotherapy is done intravenously, but, because the drugs are very toxic and not targeted, they have many adverse side effects. Another problem with intravenous drugs is that they go everywhere in the bloodstream and don’t easily cross the blood brain barrier, so little gets to the target tumors. To counteract this, high doses are necessary.
“We are trying to develop a new method of drug delivery,” Abidian says. “Not intravenous delivery, but localized directly into the tumor site.”
Current treatment already includes leaving wafers infused with the anti-tumor agent BCNU in the brain after surgery, but when the drugs in these wafers run out, repeating invasive placement is not generally recommended.
“BCNU has a half life in the body of 15 minutes,” Abidian says. “The drug needs protection because of the short half life. Encapsulation inside biodegradable polymers can solve that problem.”
Encapsulation of BCNU in microspheres has been tried before, but the resulting product didn’t have uniform size and drug distribution or high drug-encapsulation efficiency. With uniform spheres, manufacturers can design the microcapsules to precisely control the time of drug release by altering polymer composition. The tiny spheres are also injectable through the skull, obviating the need for more surgery.
For the study, published in Advanced Materials, researchers looked at using an electrojetting technique to encapsulate BCNU in poly(lactic-co-glycolic) acid, an FDA-approved biodegradable polymer.
In electrojetting, a solution containing the polymer, drug and a solvent are rapidly ejected through a tiny nozzle with the system under a voltage as high as 20 kilovolts but with only microamperage. The solvent in the liquid quickly evaporates leaving behind anything from a perfect sphere to a fiber.
“Electrojetting is a low cost, versatile approach,” Abidian says. “We can produce drug-loaded micro/nano-spheres and fibers with same size, high drug-loading capacity and high drug-encapsulation efficiency.”
The researchers tested solutions of polymer from 1 percent by weight to 10 percent by weight and found that at 1 to 2 percent they obtained flattened microspheres, at 3 to 4 percent they had microspheres, at 4 to 6 percent they had microspheres and microfibers, at 7 to 8 percent they had beaded microfibers and above 8 percent they obtained only fibers.
“Depending on the desired applications, all the shapes are useful except for the beaded fibers,” says Abidian. “While fibers are not good for drug delivery, they are good for tissue engineering applications.”
A perfect sphere
The researchers also investigated the sphericality of the spheres.
“We looked at how spherical they were and found they were perfect,” Abidian says. They have a height versus width ratio of 1.05 and they have size uniformity. A perfect sphere would have a ratio of 1.
Abidian and colleagues also looked into how BCNU releases from the microcapsules. Using mathematics, they established a drug diffusion coefficient for the encapsulation system to help in designing how much drug to include in each microcapsule and how long the microcapsules will deliver the required dosage.
BCNU is not the only drug that can be encapsulated in polymer beads for drug delivery. Other drugs can be used but would have their own diffusion coefficients and half lifes.
Source: Penn State